Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells $41,352.08 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 13,426 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total value of $41,352.08. Following the sale, the chief financial officer directly owned 1,195,349 shares in the company, valued at $3,681,674.92. This trade represents a 1.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Recursion Pharmaceuticals Trading Down 8.1%

RXRX stock opened at $3.42 on Friday. The firm has a fifty day moving average price of $4.25 and a 200 day moving average price of $4.76. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $2.98 and a fifty-two week high of $10.60. The firm has a market cap of $1.78 billion, a PE ratio of -1.90 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60.

Recursion Pharmaceuticals News Summary

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: ARK Invest/Cathie Wood bought RXRX shares, signaling conviction from a high-profile active investor and providing buying support amid recent weakness. Cathie Wood ARK ETF Buys Recursion Pharmaceuticals and CRISPR Therapeutics Shares
• Neutral Sentiment: Analyst and institutional picture is mixed — some firms (e.g., JPMorgan/Morgan Stanley/UBS in prior coverage) have high targets ~ $11 while consensus remains closer to a “Hold” and average target near $9–10, leaving valuation views split. High institutional ownership means large holders can amplify moves. MarketBeat RXRX Coverage
• Negative Sentiment: NVIDIA liquidated its entire stake in Recursion at the end of last year — a high-profile exit that markets interpret as reduced strategic endorsement and that may have pressured sentiment. Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street.
• Negative Sentiment: Reports say major backers are exiting while Recursion doubles down on its REC‑102 program — investor concern around program risk and funding runway can trigger re-pricing until clinical data reduces uncertainty. Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline
• Negative Sentiment: An insider selling disclosure: CFO Ben Taylor sold 13,426 shares at roughly $3.08 on Feb 18 — a small amount relative to his holding but often interpreted negatively in a down market. Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells 13,426 Shares of Stock

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RXRX. TD Waterhouse Canada Inc. boosted its position in shares of Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after buying an additional 2,200 shares during the period. Xponance Inc. lifted its stake in shares of Recursion Pharmaceuticals by 8.0% during the 3rd quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after acquiring an additional 2,221 shares during the last quarter. Main Management ETF Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock valued at $723,000 after acquiring an additional 2,328 shares during the period. NewEdge Advisors LLC grew its position in Recursion Pharmaceuticals by 28.1% in the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after acquiring an additional 2,428 shares during the last quarter. Finally, Equitable Holdings Inc. grew its position in Recursion Pharmaceuticals by 7.1% in the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after acquiring an additional 2,600 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RXRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Finally, Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.